Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum

[1]  R. Hyzy,et al.  Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial. , 2022, JAMA.

[2]  R. Lopes,et al.  Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial , 2021, The Lancet.

[3]  Marcelo A. Falappa,et al.  Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial , 2021, BMJ.

[4]  P. Ridker,et al.  Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. , 2021, JAMA.

[5]  J. Halperin,et al.  Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. , 2021, JAMA internal medicine.

[6]  Reamer L. Bushardt,et al.  Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID‐19: A propensity score‐matched analysis , 2021, Journal of Thrombosis and Haemostasis.

[7]  K. Khunti,et al.  Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study , 2021, BMJ.

[8]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[9]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[10]  S. Stevens,et al.  Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. , 2021, Chest.

[11]  S. Stevens,et al.  Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report - Executive Summary. , 2021, Chest.

[12]  C. Bradbury,et al.  COVID‐19 and immunothrombosis: emerging understanding and clinical management , 2021, British journal of haematology.

[13]  M. Landray,et al.  Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[14]  Á. Avezum,et al.  Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial , 2021, The Lancet.

[15]  M. Makris,et al.  Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT) , 2021, Research and Practice in Thrombosis and Haemostasis.

[16]  P. T. Ten Eyck,et al.  Standard Prophylactic Versus Intermediate Dose Enoxaparin in Adults with Severe COVID-19: A Multi-Center, Open-Label, Randomised Controlled Trial , 2021, SSRN Electronic Journal.

[17]  A. Randolph,et al.  Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C , 2021, Blood.

[18]  K. Davidson,et al.  Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry , 2021, Blood.

[19]  V. Liu,et al.  Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California. , 2021, JAMA internal medicine.

[20]  S. Parikh,et al.  Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. , 2021, JAMA.

[21]  M. Waller,et al.  Three-month follow-up of pulmonary embolism in patients with COVID-19 , 2021, Thrombosis Research.

[22]  M. Crowther,et al.  Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study , 2020, Blood Advances.

[23]  P. Monagle,et al.  Consensus‐based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID‐19–related illness , 2020, Journal of Thrombosis and Haemostasis.

[24]  S. Goldhaber,et al.  Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[25]  W. Ageno,et al.  American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. , 2020, Blood advances.

[26]  W. Aird,et al.  Postdischarge thrombosis and hemorrhage in patients with COVID-19 , 2020, Blood.

[27]  M. Whyte,et al.  Postdischarge venous thromboembolism following hospital admission with COVID-19 , 2020, Blood.

[28]  J. Thornton,et al.  Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis , 2020, BMC Pregnancy and Childbirth.

[29]  Oliver C. Grant,et al.  Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions , 2020, Antiviral Research.

[30]  A. de la Torre,et al.  Coronavirus (COVID 19) Infection in Pregnancy , 2020, Colombia medica.

[31]  Simon Li,et al.  Multisystem Inflammatory Syndrome in U.S. Children and Adolescents , 2020, The New England journal of medicine.

[32]  P. Wells,et al.  Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019 , 2020, Chest.

[33]  W. Oh,et al.  Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study , 2020, Blood.

[34]  J. Douketis,et al.  Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[35]  Arthur L. Allen,et al.  Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum , 2020, Journal of Thrombosis and Thrombolysis.

[36]  A. Falanga,et al.  ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[37]  G. Raskob,et al.  Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study , 2019, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[38]  B. Rochwerg,et al.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. , 2018, Blood advances.

[39]  G. Raskob,et al.  Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness , 2018, The New England journal of medicine.

[40]  M. Rodger,et al.  Guidance for the treatment and prevention of obstetric-associated venous thromboembolism , 2016, Journal of Thrombosis and Thrombolysis.

[41]  Kiwon Lee,et al.  High dose subcutaneous unfractionated heparin for prevention of venous thromboembolism in overweight neurocritical care patients , 2015, Journal of Thrombosis and Thrombolysis.

[42]  A. Turpie,et al.  Predictive and associative models to identify hospitalized medical patients at risk for VTE. , 2011, Chest.

[43]  F. Picard,et al.  Effect of Prophylactic Dalteparin on Anti-factor Xa Levels in Morbidly Obese Patients After Bariatric Surgery , 2010, Obesity surgery.

[44]  R. Pendleton,et al.  Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. , 2010, Thrombosis research.

[45]  J. Hirsh,et al.  Is impaired renal function a contraindication to the use of low-molecular-weight heparin? , 2002, Archives of internal medicine.

[46]  D. Scholten,et al.  A Comparison of Two Different Prophylactic Dose Regimens of Low Molecular Weight Heparin in Bariatric Surgery , 2002, Obesity surgery.

[47]  James V Lewis.  Bariatric surgery. , 2010, Southern medical journal.

[48]  E. Young.  The anti-inflammatory effects of heparin and related compounds. , 2008, Thrombosis research.